Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

(2010) Rebecca Aft et al.   LANCET ONCOLOGY

Potential Anticancer Properties of Bisphosphonates

(2010) Helen L. Neville-Webbe et al.   SEMINARS IN ONCOLOGY

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis

(2009) Kostantinos Zarogoulidis et al.   INTERNATIONAL JOURNAL OF CANCER

Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel

(2009) Filippo De Marinis et al.   Journal of Thoracic Oncology

Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer

(2009) Kishan J. Pandya et al.   LUNG CANCER

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

(2008) Allan Lipton et al.   CANCER

Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse

(2008) F.-C. Bidard et al.   CLINICAL CANCER RESEARCH

Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy*

(2008) M. Kondo et al.   CYTOTHERAPY

Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity

(2008) Vera Hirsh et al.   Journal of Thoracic Oncology